Benitec biopharma, based in Australia, has acquired the pre-clinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, Biomics Biotechnologies, based out of China. Hepbarna was developed between the two firms.
Original joint venture (JV) generated pre-clinical in vitro data sufficient to progress HBV as a therapeutic. Under new agreement, Benitec has become the sole owner of the HBV program.
Dr York Zhu, Biomics' chief executive officer said, "Biomics is pleased that our scientific contribution to the development of Hepbarna has been recognized with this agreement, and we look forward to continuing work with Benitec on new opportunities."
Benitec's chief executive officer Dr Peter French commented, "The joint venture between Benitec and Biomics allowed Benitec to enter the HBV therapeutic field and the partnership has been extremely valuable. Benitec has enjoyed an excellent working relationship with Biomics and plans to continue to explore opportunities to work with Biomics in utilizing RNA interference to target other important diseases."